Aquiva Group Inc.
AQIA
Other OTC0.12
USD
- -
- -
ISIN
US05549Q2084
CUSIP
05549Q208
Return %
Stock
S&P500
1Y
-17.33
18.21
3Y
1,924.49
64.38
5Y
-89.03
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James J. Pierce
- Full Time Employees
- 2
- Sector
- Technology
- Industry
- Software - Application
- Address
- 3131 Michelson Drive Irvine CA United States of America 92612
- IPO Date
- May 16, 2007
- Website
- aquivamedical.com
- Similar Companies
- Business
- Aquiva Group Inc. is a biotechnology company focused on the development and commercialization of advanced hydrogel-based materials for transdermal drug delivery and related wound care and skin care applications. It commercializes AquiForm™, a proprietary hydrogel platform built on HiPNA (Hydrogel with inter-Penetration Network Anchor) technology designed for enhanced API loading, controlled release, and customizable performance across medicated dressings, transdermal patches, and cosmetic-nutraceutical products. The company deploys a CDMO/Custom Design & Manufacturing model to partner with customers seeking bespoke formulations, scalable manufacturing, and accelerated development of next-generation TDDS products. Aquiva Group emphasizes material science innovations to expand beyond traditional delivery routes into broader healthcare markets, including wound care, dermatology, and cosmeceutical segments. The firm operates through collaborations and partnerships to integrate its HiPNA-enabled platforms into partner brands and clinical programs, aiming to accelerate adoption of advanced transdermal and topical therapies. Aquiva Group was founded to advance hydrogel-based delivery systems and maintains corporate operations headquartered in the United States with research and development activities and commercialization efforts aligned with global healthcare markets. The company’s product family centers on AquiForm™ and related HiPNA-driven designs, with capabilities spanning formulation development, material characterization, prototype testing, regulatory support, and scaled manufacturing services for topical and transdermal drug delivery solutions. Aquiva Group’s business structure includes strategic alliances, ODM/CDMO activities, and ongoing efforts to broaden its pipeline through new material platforms and potential expansion into adjacent therapeutic areas within wound healing, dermatology, and nutraceutical delivery. The company’s geographic focus includes markets in North America and other regions where partners seek advanced TDDS technologies, with headquarters and primary operations based in the United States and ongoing collaborations with global healthcare customers and suppliers. Aquiva Group’s governance and ownership structure include its current corporate entity status following a name transition from BHPA, Inc. to Aquiva Group Inc., reflecting its refined strategic focus on hydrogel-based medical materials and next-generation patch technologies. The company’s long-term strategy centers on expanding its AquiForm™ platform’s applicability across drug delivery modalities, enabling customers to accelerate product development timelines while delivering improved therapeutic exposure and patient experience. Aquiva Group maintains relationships with research institutions and contract manufacturing organizations to support ongoing innovation, scalable production, and commercialization of advanced hydrogel-based delivery systems across healthcare sectors.